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ABSTRACT Atopic dermatitis (AD) is a common, chronic, inflammatory, pruritic skin 
disorder that affects up to 20% of the children in Western countries. Attention-Defi-
cit/Hyperactivity disorder (ADHD) has been reported to be more frequent in chil-
dren with AD. the purpose of this study was to explore the risk for ADHD in our 
population of patients with AD. A population-based case-control study, using the 
medical database of Clalit Health Services (CHS), the largest healthcare provider or-
ganization in israel. the study included 840 patients with AD between the age of 
0-18 years and 900 age and gender frequency-matched patients without AD. the 
proportion of ADHD in patients with AD was 7.1% as compared to 4.1% in controls. 
ADHD was more frequent in boys with AD (9.6% vs. 5.2%, odds ratio (Or) 1.9, 95% 
confidence interval (Ci) 1.1-3.2) but not in girls with AD (4.6% vs. 2.9% Or 1.5). in 
multivariate analyses, AD was associated with ADHD (Or 2.1, 95% Ci 1.3-3.4). the 
current study demonstrated an association between AD and ADHD. this report and 
earlier observations emphasize the need for detection and treatment of ADHD in 
atopic patients.
KEY WORDS: atopic dermatitis, attention-deficit/hyperactivity disorder, allergy, ec-
zema, pruritus, sleep disturbances
INTRODUCTION
Atopic dermatitis (AD) is a common, chronic, in-
flammatory, pruritic skin disorder that affects up to 
20% of the children in the western countries (1). the 
eczematous, itchy skin leads to an “itch-scratch” cycle 
that in turn may cause sleep loss and psychosocial 
impairment in childhood (2-5).
Attention-Deficit/Hyperactivity disorder (ADHD) is 
a neurodevelopmental disorder that begins in child-
hood and manifests with difficulties in sustaining at-
tention and modulating the level of activity with or 
without impulsive actions. ADHD is considered to be 
the most frequent psychiatric disorder in childhood, 
with prevalence of up to 15% in Western countries 
(6). it causes impairment of quality of life, psychoso-
cial maladaptation, and economic burden through 
social services (6).
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the association and comorbidity between atopic 
diseases and ADHD had been reported in recent 
years. earlier studies failed to establish an associa-
tion between atopy and ADHD (7), but accumulating 
data, including a systematic review by Schmitt (8) and 
other recent publications (9-12), have demonstrated 
a relationship between atopic diseases and ADHD.
the purpose of this study was to examine the as-
sociation between AD and ADHD in israeli children, 
using a population-based, case-control study, as co-
morbidities in AD may have different characteristics 
in different cultural or geographic populations.
PATIENTS AND METHODS
the study was designed as a retrospective case-
control study using data mining techniques in the 
Clalit Health Services (CHS) database. CHS is the larg-
est healthcare provider organization in israel, serving 
a population of about 4 400 000 enrollees (13). CHS 
has a comprehensive computerized database with 
continuous real-time input from pharmaceutical, 
medical, and administrative computerized operating 
systems.
in the CHS database, the diagnoses of chronic 
diseases such as atopic dermatitis (AD) and atten-
tion deficit/hyperactivity disorder (ADHD) are based 
on data from hospital and primary care physician re-
ports. these diagnoses are validated using a system-
atic methodology and proven to be accurate (14). the 
CHS perform the process of validation through logis-
tic checks (such as comparing diagnoses from various 
sources) and by direct validation of the diagnoses by 
the treating physicians of each patient. 
Study patients were defined as subjects with at 
least 1 documented diagnosis of AD in the medical 
records registered by the CHS dermatologist or pedi-
atrician. the control group consisted of a computer-
generated randomly selected age- and sex-matched 
list of subjects from the CHS database, excluding pa-
tients with AD, thus sampling the general population. 
Minor differences in sex and age distribution were 
corrected using multivariate analyses. Data available 
from the CHS database included body mass index 
(BMi), age, sex, comorbid diagnoses, socio-economic 
status (SeS) and use of methylphenidate. According 
to the CHS regulations, prescriptions for methylphe-
 Characteristic
Patients with atopic 
dermatitis (n=840)
Control patients (n=900) P value
n % n %
Age (years):
Mean ± SD 9.48±3.65              10.84±3.81
Median 9                        10 <0.0001
range 2-18                       2-18
Boys 426 50.7% 458 0.490
SeS:
low 241 35.0% 455 51.9% <0.0001
intermediate 257 37.4% 311 35.5%
High 190 27.6% 111 12.7%
688 877
BMi
Mean ± SD 17.94±4.13 18.56±4.76 0.016
up to 18.5 367 65.0% 393 58.7%
18.5-24.9 159 159 28.1% 212 31.7%
25.0-29.9 27 4.8% 38 5.7% 0.200
30.0-34.9 4 0.7% 10 1.5%
35.0-39.9 1 0.2% 4 0.6%
40+ 7 1.2% 12 1.8%
565 669
received ritalin® 53 6.3% 34 3.8% 0.010
received Concerta® 18 2.1% 15 1.7% 0.290
received ritalin or Concerta® 60 7.1% 37 4.1% 0.004
SD: Standard Deviation; BMi: body-mass index
Table 1. Baseline characteristics of the study population (n=1740)
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nidate (ritalin® or Concerta®) can be issued only after 
the diagnosis has been established by specialists in 
pediatric neurology or pediatric psychiatry. thus, po-
tential selection bias related to diagnoses of ADHD by 
general pediatricians could be excluded. SeS and BMi 
were explored as potential confounding factors for 
AD and/or ADHD.
the distribution of background factors was com-
pared between patients with and without AD using 
the chi-square test for categorical variables and t-test 
for age. the proportions of patients with ADHD were 
compared between the study groups in the entire 
study sample as well as in a stratified analysis based 
on age, sex, and other subgroups using the chi-square 
test. A logistic regression model was used to measure 
the association between AD and ADHD in a multivari-
ate analysis. Statistical analysis was performed using 
SPSS software, version 12.
the study was approved by the ethics Committee 
of the CHS.
RESULTS
the study included 840 patients with AD between 
the age of 0-18 years and 900 age- and sex-matched 
children without AD (table 1). Descriptive analyses of 
the characteristics of patients with and without AD 
are shown in table 1. Patients with AD were younger 
relative to the control group (mean ± Standard Devia-
tion (SD): 9.48±3.65 years vs. 10.48±3.81 years, respec-
tively; P<0.0001). Patients with AD were of lower BMi 
than controls (17.94±4.13 vs. 18.56±4.76, respectively; 
P=0.016) and were from higher SeS (P<0.0001).
Overall, the proportion of ADHD was 7.1% in pa-
tients with AD as compared with 4.1% in the control 
group (P=0.004). Prescriptions for methylphenidate 
(ritalin® or Concerta®) were issued more commonly to 
male patients with AD as compared to male patients in 
the control group (9.6% versus 5.2%, odds ratio (Or) = 
1.9, 95% confidence interval (Ci) 1.1-3.2, P=0.009) (table 
2). Although both medications were also given more 
frequently to girls with AD than in the control group, 
the differences did not reach statistical significance 
(4.6% vs. 2.9%, Or = 1.5, 95% Ci, P=0.138) (table 3).
in a multinomial logistic regression analysis, ADHD 
was associated with AD among boys (Or = 2.1, 95% Ci 
1.3-3.4, P=0.002). Furthermore, increasing age was as-
sociated with increased risk of ADHD by 1.1 (Or = 1.2, 
95% Ci: 1.1-1.2, P<0.0001) (table 4). in contrast, SeS and 
BMi were not associated with ADHD among boys after 
controlling for the same confounders.
DISCUSSION
the finding of a higher proportion of ADHD in our 
population are in accord with earlier reports of the 
association of AD with ADHD worldwide (9-12). the 
significant sex difference in the prevalence of ADHD 
in our population reflects the generally higher rates 
of ADHD among men worldwide. this could be ex-
plained by the fact that men have 3 to 4 times higher 
incidence rates of ADHD compared to women (15).
Table 2. Atopic dermatitis (AD) and attention-deficit/hyperactivity disorder (ADHD) among boys (n=884)
Subgroups N ADHD in Atopic 
Dermatitis cases
ADHD in controls OR P value
(n=426 ) (n=458 ) (95% CI)





48 0 (0.0%) 0 (0%) - -
722 33 (7.7%) 16 (3.5%) 2.16 (1.17-4.01) 0.009
114 8 (1.9%) 8 (1.7%) 1.97 (0.67-5.71) 0.163
SeS
low 340 11 (2.6%) 7 (1.5%) 3.11 (1.17-8.25) 0.018
intermediate 293 13 (3.1%) 12 (2.6%) 1.34 (0.59-3.05) 0.309
High 160 15 (3.5%) 4 (0.9%) 2.69 (0.85-8.54) 0.065
BMi
up to 18.5 419 16 (3.7%) 10 (2.2%) 1.83 (0.81-4.14) 0.101
18.5-24.9 170 13 (3.1%) 8 (1.7%) 2.55 (0.99-6.52) 0.040
25+ 39 4 (0.9%) 3 (0.6%) 2.93 (0.55-15.63) 0.194
SeS: socio-economic status; BMi: body-mass index; Or: odds ratio; Ci: confidence interval
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the retrospective design of our study precluded 
detection of a definite causal relationship between 
AD and ADHD. it is plausible that the actual frequen-
cy of ADHD is higher in both groups, since at least 
25% of children with ADHD do not receive any treat-
ment for the disorder (16). Since patients that were 
not treated with methylphenidate were not regarded 
as having ADHD, our findings may underestimate the 
frequencies of ADHD in both groups. it is unlikely that 
patients with AD were more often prescribed therapy 
for ADHD while their skin disease is active, since the 
diagnostic criteria of ADHD mandate that “other men-
tal or psychotic disorders that could account for the 
symptoms must be excluded”. therefore, frequency 
of ADHD may be even higher among patients with 
AD, as symptoms of attention deficit and hyperactiv-
ity could be regarded as related to the insufficiently 
controlled skin disease. 
the age of patients with AD and ADHD was high-
er as compared with patients with AD but without 
ADHD. this difference may be attributed to the fact 
that the definition of ADHD in our study was based 
on prescription for the medication, which is com-
monly done at school age (17), while the diagnosis of 
AD is usually done early in infancy.
in our population, patients with AD were of high-
er SeS. SeS disadvantage is associated with higher 
risk for ADHD (18,19), while in our study the control 
group had lower SeS and yet had a lower prevalence 
of ADHD. this may indicate that our findings underes-
timate the true prevalence of ADHD among children 
with AD. 
the higher prevalence of ADHD could be related 
to the pruritus and sleep disturbances that are both 
common in AD. AD develops in early childhood and 
is frequently associated with pruritus and sleep dis-
order (2-4). Sleep disorder may affect memory, be-
havior, and the attention spectrum (2), indicating a 
potential causal risk factor for ADHD in AD. Since AD 
is a chronic inflammatory disease, the neuroimmune 
pathway theory may explain the association of ADHD 
and AD (20). Proinflammatory agents may penetrate 
the blood-brain barrier and activate behavioral and 
emotional neural pathways (21,22). Although the ma-
jority of patients with AD are usually only treated with 
topical steroids, some may need systemic courses of 
steroids that may induce hyperactivity (23). the effect 
of systemic and topical anti-inflammatory medica-
tions and antihistamines on mental health should be 
further investigated.
the strength of the present study is the use of a 
large population, including children of all ages, and us-
ing logistic regression analysis to control confounders 
such as BMi and SeS. the major limitation of our study 
is that, due to the retrospective data mining design of 
the study, we could not correlate the severity of AD 
with the severity of ADHD symptoms, a matter that 
should be further investigated in a prospective study.
Table 3. Atopic dermatitis (AD) and attention-deficit/hyperactivity disorder (ADHD) among girls (n=856)





(n =414 ) (n =442) (95% CI)





20 0 (0.0%) 0 (0.0%) - -
688 12 (2.9%) 7 (1.6%) 1.74 (0.67-4.47) 0.176
148 7 (1.7%) 6 (1.3%) 1.80 (0.57-5.66) 0.232
SeS
low 356 3 (0.7%) 7 (1.6%) 0.81 (0.20-3.21) 0.533
intermediate 272 7 (1.7%) 3 (0.7%) 1.93 (0.74-11.60) 0.100
High 141 7 (1.7%) 3 (0.7%) 1.22 (0.30-4.95) 0.539
BMi
up to 18.5 341 7 (1.7%) 2 (0.4%) 3.71 (0.76-18.15) 0.080
18.5-24.9 201 10 (2.4%) 8 (1.8%) 1.68 (0.63-4.46) 0.209
25+ 64 1 (0.2%) 2 (0.4%) 0.77 (0.06-8.97) 0.664
SeS: socio-economic status; BMi: body-mass index; Or: odds ratio; Ci: confidence interval
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CONCLUSION 
the current study demonstrated an association 
and comorbidity between AD and ADHD. this re-
port and earlier observations emphasize the need 
for early detection and treatment of ADHD in atopic 
patients that may potentially facilitate management 
of ADHD.
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